港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

科倫博泰生物

415.800

+12.4003.07%

成交量：122.55萬

成交額：5.07億

市值：968.81億

市盈率：-250.96

高：425.200

開：397.000

低：397.000

收：403.400

52周最高：581.000

52周最低：314.200

股本：2.33億

香港流通股本：1.71億

量比：1.22

換手率：0.72%

股息：- -

股息率：- -

每股收益(LYR):-1.657

淨資產收益率：-9.34%

總資產收益率：-5.11%

市淨率：17.24

市盈率(LYR):-250.96

市銷率: 40.77

資料載入中...

總覽公司新聞公告

興業證券：科倫博泰生物(06990)ASCO披露重磅肺癌數據首予「增持」評級

【券商聚焦】交銀國際：醫藥行業上半年表現整體穩健下半年內部分化或加大

異動解讀｜科倫博泰生物盤中上漲3.03%，宜聯生物和解款7.03億元到賬持續催化

港股異動 | 創新藥概念多數走高行業BD交易延續高景氣政策支持與商業化盈利兑現邏輯不變

醫藥板塊集體回升科倫博泰生物(06990)漲7.20%、榮昌生物(09995)漲6.53%

異動解讀｜科倫博泰生物盤中上漲7.35%，收到宜聯生物醫藥和解款項合計超7億元提振市場信心

科倫博泰生物(06990)收到宜聯生物醫藥根據已達成和解支付的相關款項

科倫博泰生物獲聯拓藥業6.025億元，達成YL201項目對外授權

異動解讀｜科倫博泰生物盤中下跌3.34%，生物科技板塊集體走弱疊加董事長減持壓力延續

港股異動 | 超長效抗TSLP抗體II期臨床完成首批給藥和鉑醫藥-B(02142)、科倫博泰生物(06990)盤中均升逾5%

異動解讀｜科倫博泰生物盤中上漲3.25%，多家券商維持買入評級疊加ASCO數據持續催化

科倫博泰合作伙伴Windward Bio宣佈首例患者入組SKB378/Win378針對COPD的二期Sirius研究

【券商聚焦】中信建投證券維持科倫博泰生物-B(6990.HK)「買入」評級

科倫博泰生物(06990)出現大手賣出1.98萬股，成交價$380.0，涉資752.4萬

阿斯达克财经

異動解讀｜科倫博泰生物盤中下跌3.15%，董事長持續減持疊加業績虧損擴大延續拋壓

東方證券：國產創新藥開啓NSCLC一線治療範式革新

港股創新藥概念股普漲，康諾亞-B、科倫博泰生物升逾5%

老虎资讯综合

港股異動 | 科倫博泰生物(06990)升逾7% OptiTROP-Lung05研究實現里程碑突破

異動解讀｜科倫博泰生物盤中上漲3.54%，回購計劃疊加ASCO臨床數據持續催化

異動解讀｜科倫博泰生物開盤上漲3.08%，擬回購不超過10%已發行H股提振市場信心

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hant/stock/06990/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"06990","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06990\",,,,,undefined,":{"symbol":"06990","market":"HK","secType":"STK","nameCN":"科倫博泰生物","latestPrice":415.8,"timestamp":1781770088007,"preClose":403.4,"halted":0,"volume":1225465,"delay":0,"changeRate":0.03073872087258313,"floatShares":170984257,"shares":233000000,"eps":-1.65683,"marketStatus":"休市中","change":12.4,"latestTime":"06-18 16:08:08","open":397,"high":425.2,"low":397,"amount":507498613,"amplitude":0.069906,"askPrice":415.8,"askSize":600,"bidPrice":414.4,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.843737,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1782091800000},"marketStatusCode":7,"adr":0,"listingDate":1689004800000,"exchange":"SEHK","adjPreClose":403.4,"openAndCloseTimeList":[[1781746200000,1781755200000],[1781758800000,1781769600000]],"volumeRatio":1.220825861652471,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06990\",,,,,undefined,":{"symbol":"06990","floatShares":170984257,"roa":"-5.11%","roe":"-9.34%","lyrEps":-1.65683,"volumeRatio":1.220825861652471,"shares":233000000,"dividePrice":0,"high":425.2,"amplitude":0.069906,"preClose":403.4,"low":397,"week52Low":314.2,"pbRate":"17.24","psRate":"40.77","week52High":581,"institutionHeld":0,"latestPrice":415.8,"committee":-0.714286,"eps":-1.65683,"divideRate":0,"volume":1225465,"delay":0,"ttmEps":-1.843737,"open":397,"prevYearClose":392.2,"prevWeekClose":415.2,"prevMonthClose":462,"prevQuarterClose":460,"fiveDayClose":394.4,"twentyDayClose":437,"sixtyDayClose":432.2},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/06990\",params:#limit:5,,,undefined,":[{"market":"HK","date":"2026-03-23","symbol":"06990","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1774195200000,"reportTimeType":"post","actualEps":null},{"date":"2025-08-18","symbol":"06990","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755480600000,"name":null,"time":"","dateTimestamp":1755446400000,"actualEps":null},{"date":"2025-03-24","symbol":"06990","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742779800000,"name":null,"time":"盤後","dateTimestamp":1742745600000,"actualEps":null},{"date":"2024-08-19","symbol":"06990","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724031000000,"name":null,"time":"盤後","dateTimestamp":1723996800000,"actualEps":null},{"date":"2024-03-25","symbol":"06990","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1711330200000,"name":null,"time":"","dateTimestamp":1711296000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"06990\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"06990\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.6,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":20,"updateTime":1781712000000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/06990\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"06990","date":"2026-06-18","current":-225.520234,"percent":0.212707,"low":-351.800852,"twenty":-226.404961,"median":-131.824218,"eighty":-52.561632,"high":-21.029201,"avg":-135.365211,"sd":80.163474,"marketCap":96958725910},"quantilePoints":[{"date":"2023-07-14","current":-21.13661,"twenty":-21.950454,"median":-21.915957,"eighty":-21.591449,"marketCap":14244687534},{"date":"2023-07-21","current":-23.970152,"twenty":-21.950454,"median":-21.798359,"eighty":-21.186829,"marketCap":16079230625},{"date":"2023-07-28","current":-25.171471,"twenty":-24.928642,"median":-21.953758,"eighty":-21.326081,"marketCap":16867005011},{"date":"2023-08-04","current":-23.795235,"twenty":-24.81024,"median":-23.425444,"eighty":-21.637654,"marketCap":15971316326},{"date":"2023-08-11","current":-25.354634,"twenty":-24.81024,"median":-23.323535,"eighty":-21.856149,"marketCap":16921892522},{"date":"2023-08-18","current":-27.290696,"twenty":-25.136334,"median":-23.811022,"eighty":-21.920213,"marketCap":18083628667},{"date":"2023-08-25","current":-27.955027,"twenty":-25.91111,"median":-24.066367,"eighty":-21.957062,"marketCap":18532979440},{"date":"2023-09-01","current":-41.23344,"twenty":-27.36684,"median":-24.766756,"eighty":-21.989236,"marketCap":16768455673},{"date":"2023-09-08","current":-41.179226,"twenty":-40.625811,"median":-24.994187,"eighty":-22.159386,"marketCap":16549260174},{"date":"2023-09-15","current":-42.756679,"twenty":-41.200358,"median":-25.354634,"eighty":-22.761005,"marketCap":17316444421},{"date":"2023-09-22","current":-42.808543,"twenty":-42.12743,"median":-25.915972,"eighty":-23.169807,"marketCap":17261645546},{"date":"2023-09-29","current":-41.568511,"twenty":-42.347449,"median":-27.197776,"eighty":-23.343916,"marketCap":16790375223},{"date":"2023-10-06","current":-41.914184,"twenty":-42.346401,"median":-27.481057,"eighty":-23.57336,"marketCap":16921892522},{"date":"2023-10-13","current":-45.021843,"twenty":-42.393899,"median":-34.166325,"eighty":-23.80155,"marketCap":18149387317},{"date":"2023-10-20","current":-39.509362,"twenty":-42.529229,"median":-40.304828,"eighty":-23.874674,"marketCap":15902633452},{"date":"2023-10-27","current":-41.923505,"twenty":-42.45246,"median":-40.317099,"eighty":-23.977981,"marketCap":16867093648},{"date":"2023-11-03","current":-44.17615,"twenty":-43.157759,"median":-40.968576,"eighty":-24.032126,"marketCap":17820594068},{"date":"2023-11-10","current":-48.451746,"twenty":-43.729096,"median":-41.213927,"eighty":-24.147781,"marketCap":19541278735},{"date":"2023-11-17","current":-48.422639,"twenty":-44.163404,"median":-41.246315,"eighty":-24.349478,"marketCap":19705675360},{"date":"2023-11-24","current":-47.973827,"twenty":-44.628759,"median":-41.529173,"eighty":-24.780872,"marketCap":19683755810},{"date":"2023-12-01","current":-50.941262,"twenty":-45.174782,"median":-41.90853,"eighty":-24.844962,"marketCap":20987969029},{"date":"2023-12-08","current":-50.880899,"twenty":-46.685504,"median":-41.9817,"eighty":-24.922954,"marketCap":20878371279},{"date":"2023-12-15","current":-53.058458,"twenty":-47.438439,"median":-42.172758,"eighty":-25.124621,"marketCap":21897630350},{"date":"2023-12-22","current":-55.272951,"twenty":-48.26932,"median":-42.355666,"eighty":-25.208104,"marketCap":22796331896},{"date":"2023-12-29","current":-54.398289,"twenty":-48.483234,"median":-42.389893,"eighty":-25.318001,"marketCap":22555216847},{"date":"2024-01-05","current":-54.305497,"twenty":-48.692055,"median":-42.518207,"eighty":-25.505631,"marketCap":22357940898},{"date":"2024-01-12","current":-58.852865,"twenty":-49.706536,"median":-42.808543,"eighty":-25.777515,"marketCap":24243022189},{"date":"2024-01-19","current":-48.649703,"twenty":-50.614438,"median":-43.44751,"eighty":-25.920835,"marketCap":20012549058},{"date":"2024-01-26","current":-45.202208,"twenty":-50.432693,"median":-43.523908,"eighty":-26.320623,"marketCap":18522019665},{"date":"2024-02-02","current":-38.832469,"twenty":-50.323187,"median":-43.65215,"eighty":-26.948338,"marketCap":15891673677},{"date":"2024-02-09","current":-43.972121,"twenty":-49.706536,"median":-43.780393,"eighty":-27.253528,"marketCap":18083628667},{"date":"2024-02-16","current":-51.156498,"twenty":-50.095577,"median":-43.99523,"eighty":-27.328768,"marketCap":21042767904},{"date":"2024-02-23","current":-57.052501,"twenty":-50.855188,"median":-44.095348,"eighty":-27.575851,"marketCap":23344320643},{"date":"2024-03-01","current":-55.517903,"twenty":-51.144997,"median":-44.174132,"eighty":-27.979787,"marketCap":22730573246},{"date":"2024-03-08","current":-62.556972,"twenty":-52.587613,"median":-44.308071,"eighty":-30.229554,"marketCap":25623953833},{"date":"2024-03-15","current":-80.340969,"twenty":-54.14227,"median":-44.794506,"eighty":-38.844663,"marketCap":32879324850},{"date":"2024-03-22","current":-87.812662,"twenty":-54.39157,"median":-45.089055,"eighty":-38.957109,"marketCap":35904222736},{"date":"2024-03-28","current":-54.646477,"twenty":-54.498503,"median":-45.202208,"eighty":-39.211798,"marketCap":33975302345},{"date":"2024-04-05","current":-48.790889,"twenty":-54.557693,"median":-45.399289,"eighty":-39.390336,"marketCap":30314737511},{"date":"2024-04-12","current":-51.407626,"twenty":-54.48688,"median":-46.006494,"eighty":-39.95604,"marketCap":31958703754},{"date":"2024-04-19","current":-48.134373,"twenty":-54.430626,"median":-46.386128,"eighty":-40.284427,"marketCap":29898266063},{"date":"2024-04-26","current":-71.709655,"twenty":-54.881886,"median":-46.751052,"eighty":-40.312191,"marketCap":36824843832},{"date":"2024-05-03","current":-70.050704,"twenty":-55.277405,"median":-46.894686,"eighty":-40.440284,"marketCap":35948061836},{"date":"2024-05-10","current":-80.537958,"twenty":-55.535893,"median":-47.299854,"eighty":-40.706984,"marketCap":41427949311},{"date":"2024-05-17","current":-72.846762,"twenty":-56.640749,"median":-47.434905,"eighty":-40.885351,"marketCap":37416671679},{"date":"2024-05-24","current":-76.490072,"twenty":-57.838988,"median":-47.480121,"eighty":-41.121673,"marketCap":39198277014},{"date":"2024-05-31","current":-74.804992,"twenty":-59.45269,"median":-48.0541,"eighty":-41.186166,"marketCap":38373753847},{"date":"2024-06-07","current":-77.551054,"twenty":-62.567703,"median":-48.422639,"eighty":-41.217553,"marketCap":39733102851},{"date":"2024-06-14","current":-71.048454,"twenty":-63.220056,"median":-48.609184,"eighty":-41.232055,"marketCap":36368156956},{"date":"2024-06-21","current":-75.38559,"twenty":-65.709636,"median":-48.654461,"eighty":-41.23344,"marketCap":38507460307},{"date":"2024-06-28","current":-72.361795,"twenty":-70.050704,"median":-48.790889,"eighty":-41.25919,"marketCap":36947551614},{"date":"2024-07-05","current":-71.32983,"twenty":-70.110492,"median":-48.913989,"eighty":-41.293743,"marketCap":36412725776},{"date":"2024-07-12","current":-64.338068,"twenty":-69.786991,"median":-49.290918,"eighty":-41.483815,"marketCap":32891789012},{"date":"2024-07-19","current":-64.816339,"twenty":-69.10708,"median":-50.290098,"eighty":-41.560643,"marketCap":33136917521},{"date":"2024-07-26","current":-64.836994,"twenty":-68.943217,"median":-50.396598,"eighty":-41.836002,"marketCap":33270623980},{"date":"2024-08-02","current":-67.177788,"twenty":-68.832021,"median":-50.583009,"eighty":-41.911922,"marketCap":34451697705},{"date":"2024-08-09","current":-67.337335,"twenty":-68.832021,"median":-50.91108,"eighty":-41.921641,"marketCap":34763679444},{"date":"2024-08-16","current":-69.468586,"twenty":-68.832021,"median":-51.098991,"eighty":-41.970061,"marketCap":35877899939},{"date":"2024-08-23","current":-143.952492,"twenty":-69.519081,"median":-51.282062,"eighty":-42.023931,"marketCap":36568716645},{"date":"2024-08-30","current":-142.905377,"twenty":-70.543671,"median":-51.775379,"eighty":-42.069838,"marketCap":36546432236},{"date":"2024-09-06","current":-147.713941,"twenty":-71.622574,"median":-52.451442,"eighty":-42.229208,"marketCap":37794359190},{"date":"2024-09-13","current":-159.71572,"twenty":-72.235174,"median":-53.058458,"eighty":-42.319371,"marketCap":40758185707},{"date":"2024-09-20","current":-153.295015,"twenty":-72.624329,"median":-53.663008,"eighty":-42.346401,"marketCap":39354267883},{"date":"2024-09-27","current":-152.378595,"twenty":-73.54444,"median":-54.299669,"eighty":-42.364187,"marketCap":39354267883},{"date":"2024-10-04","current":-188.785359,"twenty":-74.133327,"median":-54.381491,"eighty":-42.385888,"marketCap":48535444762},{"date":"2024-10-10","current":-168.292174,"twenty":-74.96999,"median":-54.488817,"eighty":-42.420555,"marketCap":42986626697},{"date":"2024-10-18","current":-169.261982,"twenty":-75.395206,"median":-54.742682,"eighty":-42.48514,"marketCap":43008911107},{"date":"2024-10-25","current":-173.131782,"twenty":-76.300948,"median":-55.181976,"eighty":-42.60999,"marketCap":43989425142},{"date":"2024-11-01","current":-155.135166,"twenty":-77.964709,"median":-55.298647,"eighty":-42.767052,"marketCap":39443405523},{"date":"2024-11-08","current":-154.553256,"twenty":-78.843611,"median":-55.532894,"eighty":-42.819467,"marketCap":38997717325},{"date":"2024-11-15","current":-143.716763,"twenty":-80.792913,"median":-56.569783,"eighty":-42.897746,"marketCap":35989321988},{"date":"2024-11-22","current":-149.571879,"twenty":-86.542136,"median":-57.071537,"eighty":-43.077872,"marketCap":37437808632},{"date":"2024-11-29","current":-163.214034,"twenty":-139.660525,"median":-57.926605,"eighty":-43.27892,"marketCap":40825038936},{"date":"2024-12-06","current":-164.492389,"twenty":-143.07608,"median":-58.601892,"eighty":-43.427612,"marketCap":41047883035},{"date":"2024-12-13","current":-167.859925,"twenty":-143.961595,"median":-59.46824,"eighty":-43.489321,"marketCap":41805552972},{"date":"2024-12-20","current":-160.518216,"twenty":-146.054141,"median":-61.493522,"eighty":-43.569737,"marketCap":39799956081},{"date":"2024-12-27","current":-154.616488,"twenty":-147.398806,"median":-62.556972,"eighty":-43.707223,"marketCap":38306900618},{"date":"2025-01-03","current":-146.467928,"twenty":-147.580179,"median":-62.909234,"eighty":-43.769457,"marketCap":36323588137},{"date":"2025-01-10","current":-149.189796,"twenty":-147.713941,"median":-63.270129,"eighty":-43.89543,"marketCap":36858413974},{"date":"2025-01-17","current":-146.545949,"twenty":-148.128618,"median":-63.821936,"eighty":-43.999852,"marketCap":36234450497},{"date":"2025-01-24","current":-151.096908,"twenty":-148.795989,"median":-64.223738,"eighty":-44.022873,"marketCap":37593799501},{"date":"2025-01-28","current":-144.751587,"twenty":-148.750633,"median":-64.3181,"eighty":-44.025895,"marketCap":36203787461},{"date":"2025-02-07","current":-162.755483,"twenty":-148.864023,"median":-64.816339,"eighty":-44.095348,"marketCap":40476425278},{"date":"2025-02-14","current":-166.856795,"twenty":-150.654332,"median":-65.202788,"eighty":-44.112421,"marketCap":41476404342},{"date":"2025-02-21","current":-194.414734,"twenty":-151.676932,"median":-65.382992,"eighty":-44.172115,"marketCap":48498984584},{"date":"2025-02-28","current":-211.14481,"twenty":-152.24965,"median":-65.712478,"eighty":-44.17615,"marketCap":52498900839},{"date":"2025-03-07","current":-225.41295,"twenty":-152.905086,"median":-66.309677,"eighty":-44.219461,"marketCap":56271549124},{"date":"2025-03-14","current":-227.151092,"twenty":-153.295015,"median":-66.812487,"eighty":-44.308071,"marketCap":56726085062},{"date":"2025-03-21","current":-236.708664,"twenty":-154.553256,"median":-67.337335,"eighty":-44.550078,"marketCap":59089671940},{"date":"2025-03-28","current":-231.805328,"twenty":-155.61149,"median":-67.803663,"eighty":-44.648429,"marketCap":66180441600},{"date":"2025-04-03","current":-246.46154,"twenty":-156.727441,"median":-67.952396,"eighty":-44.882152,"marketCap":70225812000},{"date":"2025-04-11","current":-242.489155,"twenty":-158.779779,"median":-68.515098,"eighty":-45.005591,"marketCap":68634936000},{"date":"2025-04-17","current":-228.611836,"twenty":-159.44307,"median":-68.80487,"eighty":-45.06217,"marketCap":64862287200},{"date":"2025-04-25","current":-235.137362,"twenty":-160.624501,"median":-68.953584,"eighty":-45.131919,"marketCap":66771338400},{"date":"2025-05-02","current":-274.570331,"twenty":-161.195254,"median":-69.468586,"eighty":-45.197413,"marketCap":78134738400},{"date":"2025-05-09","current":-249.374354,"twenty":-161.514906,"median":-70.050704,"eighty":-45.202208,"marketCap":71462875059},{"date":"2025-05-16","current":-247.507619,"twenty":-162.87029,"median":-70.732965,"eighty":-45.217068,"marketCap":71507400214},{"date":"2025-05-23","current":-244.618313,"twenty":-163.824551,"median":-71.32983,"eighty":-45.58151,"marketCap":70884048033},{"date":"2025-05-30","current":-244.159494,"twenty":-165.025774,"median":-71.669987,"eighty":-45.601984,"marketCap":71062148656},{"date":"2025-06-06","current":-258.187076,"twenty":-166.004403,"median":-72.203519,"eighty":-46.006494,"marketCap":75336563613},{"date":"2025-06-13","current":-271.678883,"twenty":-167.701589,"median":-72.488214,"eighty":-46.133909,"marketCap":79304691313},{"date":"2025-06-20","current":-252.757485,"twenty":-168.349452,"median":-72.789206,"eighty":-46.315126,"marketCap":73636805593},{"date":"2025-06-27","current":-255.806605,"twenty":-169.647858,"median":-73.569836,"eighty":-46.457129,"marketCap":74733815733},{"date":"2025-07-04","current":-283.173205,"twenty":-171.495185,"median":-73.869687,"eighty":-46.685504,"marketCap":82732847998},{"date":"2025-07-11","current":-266.231967,"twenty":-173.142078,"median":-74.539848,"eighty":-46.749361,"marketCap":77704884860},{"date":"2025-07-18","current":-304.526119,"twenty":-187.755426,"median":-75.01675,"eighty":-46.798833,"marketCap":88812112519},{"date":"2025-07-25","current":-289.211949,"twenty":-196.095673,"median":-75.38559,"eighty":-46.877904,"marketCap":84652615741},{"date":"2025-08-01","current":-318.351212,"twenty":-209.071662,"median":-75.715906,"eighty":-46.908544,"marketCap":92605939250},{"date":"2025-08-08","current":-315.832709,"twenty":-214.487876,"median":-76.34536,"eighty":-47.149906,"marketCap":92103142937},{"date":"2025-08-15","current":-340.637946,"twenty":-221.73884,"median":-77.157567,"eighty":-47.354138,"marketCap":99188000086},{"date":"2025-08-22","current":-135.707825,"twenty":-221.73884,"median":-78.335478,"eighty":-47.421279,"marketCap":106638527281},{"date":"2025-08-29","current":-131.473703,"twenty":-217.466422,"median":-78.819337,"eighty":-47.438439,"marketCap":103804584421},{"date":"2025-09-05","current":-151.82862,"twenty":-215.82299,"median":-80.340969,"eighty":-47.449348,"marketCap":119756940196},{"date":"2025-09-12","current":-146.494298,"twenty":-214.791029,"median":-81.555855,"eighty":-47.474394,"marketCap":115757424063},{"date":"2025-09-19","current":-147.466634,"twenty":-214.487876,"median":-85.53437,"eighty":-47.73502,"marketCap":116443055400},{"date":"2025-09-26","current":-143.954691,"twenty":-214.295448,"median":-89.950081,"eighty":-47.938811,"marketCap":113375018127},{"date":"2025-10-03","current":-165.853778,"twenty":-213.463042,"median":-128.34687,"eighty":-48.070155,"marketCap":130933921593},{"date":"2025-10-10","current":-144.531455,"twenty":-212.219938,"median":-131.729362,"eighty":-48.217901,"marketCap":113934664453},{"date":"2025-10-17","current":-135.703716,"twenty":-210.108236,"median":-132.867642,"eighty":-48.374971,"marketCap":106892448189},{"date":"2025-10-24","current":-129.499037,"twenty":-207.014216,"median":-133.546653,"eighty":-48.434282,"marketCap":102042180034},{"date":"2025-10-31","current":-132.379263,"twenty":-204.550971,"median":-132.326202,"eighty":-48.483234,"marketCap":104467314112},{"date":"2025-11-07","current":-120.930715,"twenty":-203.710245,"median":-131.985022,"eighty":-48.610423,"marketCap":95373061321},{"date":"2025-11-14","current":-137.099974,"twenty":-201.138492,"median":-131.729362,"eighty":-48.622244,"marketCap":108431475585},{"date":"2025-11-21","current":-125.836792,"twenty":-194.360264,"median":-130.233026,"eighty":-48.651606,"marketCap":99477134375},{"date":"2025-11-28","current":-134.139839,"twenty":-194.090443,"median":-131.64896,"eighty":-48.675637,"marketCap":106426076251},{"date":"2025-12-05","current":-134.965867,"twenty":-192.863217,"median":-131.473703,"eighty":-48.751223,"marketCap":107265545740},{"date":"2025-12-12","current":-128.449432,"twenty":-188.527876,"median":-130.526276,"eighty":-48.814858,"marketCap":102275366003},{"date":"2025-12-19","current":-122.479247,"twenty":-187.446049,"median":-129.499037,"eighty":-48.911385,"marketCap":97751558204},{"date":"2025-12-24","current":-122.098928,"twenty":-187.290368,"median":-128.758533,"eighty":-48.913338,"marketCap":97751558204},{"date":"2026-01-02","current":-116.223952,"twenty":-179.729041,"median":-128.478737,"eighty":-49.104524,"marketCap":93414299181},{"date":"2026-01-09","current":-137.872108,"twenty":-173.799059,"median":-128.508043,"eighty":-49.251224,"marketCap":111089795631},{"date":"2026-01-16","current":-136.67551,"twenty":-173.152374,"median":-129.252083,"eighty":-49.296233,"marketCap":110483512112},{"date":"2026-01-23","current":-124.044288,"twenty":-172.874196,"median":-128.511935,"eighty":-49.590244,"marketCap":100176692282},{"date":"2026-01-30","current":-119.398299,"twenty":-172.654145,"median":-128.43808,"eighty":-50.08289,"marketCap":96865451522},{"date":"2026-02-06","current":-121.3325,"twenty":-172.20913,"median":-127.906249,"eighty":-50.304899,"marketCap":98684302080},{"date":"2026-02-13","current":-119.328264,"twenty":-171.604872,"median":-127.229577,"eighty":-50.349599,"marketCap":97611646623},{"date":"2026-02-20","current":-118.929435,"twenty":-171.385498,"median":-126.777731,"eighty":-50.372821,"marketCap":97145274685},{"date":"2026-02-27","current":-109.393801,"twenty":-170.608939,"median":-126.362178,"eighty":-50.420375,"marketCap":90336244390},{"date":"2026-03-06","current":-109.941252,"twenty":-169.952459,"median":-125.237252,"eighty":-50.5225,"marketCap":90056421227},{"date":"2026-03-13","current":-111.874188,"twenty":-169.826622,"median":-125.028422,"eighty":-50.583009,"marketCap":92061820561},{"date":"2026-03-20","current":-118.784792,"twenty":-169.647858,"median":-124.510593,"eighty":-50.752344,"marketCap":97378460654},{"date":"2026-03-27","current":-246.717525,"twenty":-170.608939,"median":-124.791344,"eighty":-50.880899,"marketCap":106705913600},{"date":"2026-04-02","current":-270.1664,"twenty":-172.638036,"median":-125.053164,"eighty":-50.929189,"marketCap":117409151000},{"date":"2026-04-10","current":-262.507699,"twenty":-173.162671,"median":-125.237252,"eighty":-50.974222,"marketCap":114960698000},{"date":"2026-04-17","current":-276.768173,"twenty":-188.270393,"median":-126.362178,"eighty":-51.053793,"marketCap":121256720000},{"date":"2026-04-24","current":-263.25072,"twenty":-199.457552,"median":-126.777731,"eighty":-51.109685,"marketCap":115341038016},{"date":"2026-04-30","current":-249.758244,"twenty":-207.783795,"median":-127.598017,"eighty":-51.131881,"marketCap":109457493848},{"date":"2026-05-08","current":-237.123047,"twenty":-214.424086,"median":-128.140667,"eighty":-51.206724,"marketCap":104280765336},{"date":"2026-05-15","current":-230.895214,"twenty":-220.549694,"median":-128.478737,"eighty":-51.422215,"marketCap":101808994065},{"date":"2026-05-22","current":-251.35436,"twenty":-225.355554,"median":-129.00513,"eighty":-51.539533,"marketCap":110576786499},{"date":"2026-05-29","current":-244.039033,"twenty":-227.151092,"median":-129.499037,"eighty":-51.775379,"marketCap":107731917678},{"date":"2026-06-05","current":-207.501784,"twenty":-227.151092,"median":-130.526276,"eighty":-51.91711,"marketCap":91735360204},{"date":"2026-06-12","current":-219.148588,"twenty":-226.740676,"median":-131.473703,"eighty":-52.267792,"marketCap":96818814328},{"date":"2026-06-18","current":-218.939992,"twenty":-226.404961,"median":-131.824218,"eighty":-52.561632,"marketCap":96958725910}],"updateTime":1782001355797},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"06990\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2644705357","title":"興業證券：科倫博泰生物(06990)ASCO披露重磅肺癌數據 首予「增持」評級","url":"https://stock-news.laohu8.com/highlight/detail?id=2644705357","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644705357?lang=zh_tw&edition=fundamental","pubTime":"2026-06-18 15:51","pubTimestamp":1781769060,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，兴业证券发布研报称，科伦博泰生物在2026年ASCO大会上口头报告了sac-TMT联合K药一线治疗PD-L1TPS≥1% NSCLC的III期OptiTROP-Lung05研究结果。该行预计2026年至2028年收入分别为35.87亿元、43.55亿元、67.12亿元，归母净利润分别为0.75亿元、4.98亿元、14.34亿元，首次覆盖，给予“增持”评级。兴业证券主要观点如下：一线NSCLC大适应症临床3期数据意义重大该临床共有413例患者被随机(1:1)分配接受sac-TMT联合K药或K药单药治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456076.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601377","06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643822932","title":"【券商聚焦】交銀國際：醫藥行業上半年表現整體穩健 下半年內部分化或加大","url":"https://stock-news.laohu8.com/highlight/detail?id=2643822932","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643822932?lang=zh_tw&edition=fundamental","pubTime":"2026-06-15 10:21","pubTimestamp":1781490116,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，医药行业在1H26表现整体稳健、但内部分化也较为明显。短期关注出海交易、业绩表现和利好政策落地。推荐高景气度赛道中、投资性价比较高的头部玩家，包括药明合联、凯莱英和康龙化成。2026年港股龙头收入和净利润增速有望稳定在双位数。板块复苏积极信号已经出现。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983754","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YR35.GBP","09926","06821","01093","LU0502904849.HKD","01530","06990","01952","LU3063872942.SGD","LU0819121731.USD","LU2097828631.EUR","LU0051755006.USD","LU0348827113.USD","01951","02273","IE00B0JY6N72.USD","LU1226287875.USD","02269","LU1688375341.USD","03692","09996","00013","03329","01177","01801","02162","LU2399975544.HKD","02596","01548","02268","02096","09966","LU0320764599.SGD","LU0181495838.USD","HK0000306685.HKD","06160","06078","LU1960683339.HKD","03759","LU0737861772.HKD","01276","LU1242518857.USD","06996","LU1880383366.USD","BK1191","HK0000320264.USD","BK1576","LU0456827905.SGD","SG9999002562.SGD","LU0140636845.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141452520","title":"異動解讀｜科倫博泰生物盤中上漲3.03%，宜聯生物和解款7.03億元到賬持續催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1141452520","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141452520?lang=zh_tw&edition=fundamental","pubTime":"2026-06-15 09:54","pubTimestamp":1781488488,"startTime":"0","endTime":"0","summary":"6月15日，科伦博泰生物盘中上涨3.03%，报420.2港元，成交额6105.08万港元。消息面上，公司于6月12日公告披露，已收到宜联生物医药根据和解协议支付的款项合计人民币7.03亿元，其中包含YL201对外授权应分享给公司的收入6.025亿元。根据双方和解协议，宜联生物需就其管线内包括YL201、YL212等6款ADC药物向科伦博泰分享对外授权收入及净利润，7.03亿元为\"首期兑现\"，后续管线授权里程碑达成及产品商业化仍有持续分成空间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642257792","title":"港股異動 | 創新藥概念多數走高 行業BD交易延續高景氣 政策支持與商業化盈利兑現邏輯不變","url":"https://stock-news.laohu8.com/highlight/detail?id=2642257792","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642257792?lang=zh_tw&edition=fundamental","pubTime":"2026-06-12 14:50","pubTimestamp":1781247029,"startTime":"0","endTime":"0","summary":"消息面上，今年一季度，中国创新药对外授权交易总额突破600亿美元，显示出海已从“偶发大单”升级为可持续的产业能力；另一方面，ASCO 2026中国研究入选数量和学术层级也在继续提升。近期多个创新药数据读出，重要BD陆续公告，事件性催化不断；中国创新药全球竞争力持续加强，政策支持与商业化盈利兑现的产业逻辑不变。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453619.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0196878994.USD","VXUS","BK4588","LU2543165471.USD","BK1161","BK1574","09969","LU1969619763.USD","LU0359201612.USD","LU2328871848.SGD","BK4585","01276","06978","LU0359202008.SGD","159992","BK1191","09995","06990","LU1023057109.AUD","LU0359201885.HKD","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642254781","title":"醫藥板塊集體回升 科倫博泰生物(06990)漲7.20%、榮昌生物(09995)漲6.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2642254781","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642254781?lang=zh_tw&edition=fundamental","pubTime":"2026-06-12 13:30","pubTimestamp":1781242214,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股医药板块集体回升，科伦博泰生物 涨7.20%，荣昌生物涨6.53%，康诺亚-B涨5.58%，复宏汉霖涨5.36%，康方生物涨5.07%，君实生物涨4.61%，药明合联涨4.06%，诺诚健华涨3.96%。英伟达同时为 Abridge 投资方，新模型基于英伟达开放模型套件 Nemotron 训练，Abridge 将采用去标识化临床数据进行定制优化，预计 2026 年晚些时候上线。东莞证券研报认为，受行业合规整顿以及消费疲软等因素影响，2025年医药生物行业整体归母净利润同比有所下滑。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983673","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000320223.HKD","HK0000165453.HKD","LU1720050803.USD","02162","LU1794554557.SGD","BK1583","LU0348767384.USD","LU1961090484.USD","09926","BK1141","LU1969619763.USD","02696","LU2476274720.SGD","LU0348766576.USD","HK0000306701.USD","LU0348784397.USD","LU0348827113.USD","LU0417516571.SGD","BK1515","LU1064130708.USD","HK0000320264.USD","LU1064131003.USD","LU0540923850.HKD","LU2488822045.USD","LU0417516738.SGD","688331","HK0000306685.HKD","LU0348735423.USD","LU0348783233.USD","LU0417516902.SGD","LU0634319403.HKD","LU2148510915.USD","SG9999014674.SGD","LU2476274308.USD","09969","06990","BK0239","BK1161","BK1574","BK1587","IE00BPRC5H50.USD","LU0561508036.HKD","09995","LU2399975544.HKD","LU0348825331.USD","09939","02268","LU2328871848.SGD","01877","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199518915","title":"異動解讀｜科倫博泰生物盤中上漲7.35%，收到宜聯生物醫藥和解款項合計超7億元提振市場信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1199518915","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199518915?lang=zh_tw&edition=fundamental","pubTime":"2026-06-12 11:01","pubTimestamp":1781233269,"startTime":"0","endTime":"0","summary":"6月12日，科伦博泰生物盘中上涨7.35%，报423.4港元，成交额1.8亿港元。消息面上，公司当日公告，已收到宜联生物医药就YL201对外授权应分享给公司的收入人民币6.025亿元，截至公告日已累计收到和解款项合计人民币7.027亿元，大额现金回流显著改善公司资金面。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642307622","title":"科倫博泰生物(06990)收到宜聯生物醫藥根據已達成和解支付的相關款項","url":"https://stock-news.laohu8.com/highlight/detail?id=2642307622","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642307622?lang=zh_tw&edition=fundamental","pubTime":"2026-06-12 08:02","pubTimestamp":1781222538,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦博泰生物(06990)发布公告，有关本公司与苏州宜联生物医药有限公司(宜联生物医药)、薛彤彤博士、肖亮博士及蔡家强博士订立和解协议的相关事宜。根据已达成和解，本公司近日已收到宜联生物医药就YL201对外授权应分享给本公司的收入人民币6.025亿元。于2026年度及截至本公告日，本公司已收到宜联生物医药根据已达成和解支付的相关款项合计人民币7.027亿(包含前述人民币6.025亿元)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453467.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","161726","LU0196878994.USD","XBI","06990","399441","BK1161","BK4581","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125223340","title":"科倫博泰生物獲聯拓藥業6.025億元，達成YL201項目對外授權","url":"https://stock-news.laohu8.com/highlight/detail?id=1125223340","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125223340?lang=zh_tw&edition=fundamental","pubTime":"2026-06-12 07:52","pubTimestamp":1781221941,"startTime":"0","endTime":"0","summary":"科伦博泰生物宣布，已与联拓药业就YL201项目达成对外授权协议，并据此获得总计6.025亿元人民币的款项。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU0196878994.USD","06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126254438","title":"異動解讀｜科倫博泰生物盤中下跌3.34%，生物科技板塊集體走弱疊加董事長減持壓力延續","url":"https://stock-news.laohu8.com/highlight/detail?id=1126254438","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126254438?lang=zh_tw&edition=fundamental","pubTime":"2026-06-11 10:02","pubTimestamp":1781143341,"startTime":"0","endTime":"0","summary":"6月11日，科伦博泰生物盘中下跌3.34%，报388.2港元，成交额5014.49万港元。板块层面，生物科技行业今日整体承压，百济神州跌2.94%、康方生物跌2.9%、三生制药跌2.55%、信达生物跌1.61%，创新药资产延续调整态势。个股层面，公司此前披露的业绩显示净亏损扩大至3.82亿元，授权及里程碑收入大幅缩减、研发费用高企为主要拖累，同时董事长连续减持信号持续压制短期市场信心。尽管多家券商近日维持\"买入\"评级且ASCO临床数据表现积极，但板块系统性走弱下个股仍难以独善其身。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642105174","title":"港股異動 | 超長效抗TSLP抗體II期臨床完成首批給藥 和鉑醫藥-B(02142)、科倫博泰生物(06990)盤中均升逾5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2642105174","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642105174?lang=zh_tw&edition=fundamental","pubTime":"2026-06-10 13:45","pubTimestamp":1781070342,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和铂医药-B、科伦博泰生物今日逆市走高，截至发稿，和铂医药涨3.46%，报9.86港元；科伦博泰生物涨3.82%，报402.2港元。消息面上，6月9日，科伦博泰宣布，其合作伙伴Windward Bio主导的一项II期临床研究已完成首批患者给药。据悉，SKB378/WIN378最初由科伦博泰与和铂医药共同开发，双方平分全球权益。若后续临床试验顺利推进，SKB378/WIN378有望成为首款获批上市的超长效抗TSLP抗体，用于哮喘和COPD治疗。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452439.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06990","BK1161","BK1583","LU0196878994.USD","BK4588","VXUS","02142","BK4585","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187758017","title":"異動解讀｜科倫博泰生物盤中上漲3.25%，多家券商維持買入評級疊加ASCO數據持續催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1187758017","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187758017?lang=zh_tw&edition=fundamental","pubTime":"2026-06-10 11:53","pubTimestamp":1781063609,"startTime":"0","endTime":"0","summary":"6月10日，科伦博泰生物盘中上涨3.25%，报400.0港元，成交额1.38亿港元。消息面上，野村近日维持公司\"买入\"评级并将目标价上调至544.42港元，中信建投亦维持\"买入\"评级，核心逻辑均指向公司芦康沙妥珠单抗III期OptiTROP-Lung05研究数据，联合用药组PFS风险比达0.35，系全球首个在PD-L1阳性非小细胞肺癌中显示PFS改善的ADC药物，成果已同步发表于《柳叶刀》。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166735631","title":"科倫博泰合作伙伴Windward Bio宣佈首例患者入組SKB378/Win378針對COPD的二期Sirius研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1166735631","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166735631?lang=zh_tw&edition=fundamental","pubTime":"2026-06-09 20:14","pubTimestamp":1781007283,"startTime":"0","endTime":"0","summary":"科伦博泰生物的合作方Windward Bio近日宣布，其用于治疗慢性阻塞性肺病的候选药物SKB378/Win378，已在名为“Sirius”的第二期临床研究中完成了对首批患者的给药。Sirius研究旨在评估SKB378/Win378在COPD患者中的安全性、耐受性及初步疗效，为后续的临床开发决策提供重要数据支持。此次研究的启动，是基于此前临床前及早期临床研究中观察到的积极信号。Windward Bio与科伦博泰生物的合作，整合了双方在药物研发领域的专业优势，共同推进该候选药物的开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990","BK1161","LU0196878994.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642581466","title":"【券商聚焦】中信建投證券維持科倫博泰生物-B(6990.HK)「買入」評級","url":"https://stock-news.laohu8.com/highlight/detail?id=2642581466","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642581466?lang=zh_tw&edition=fundamental","pubTime":"2026-06-09 17:26","pubTimestamp":1780997189,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券发布研报指，科伦博泰生物-B 在2026年ASCO大会上公布核心产品Sac-TMT联合帕博利珠单抗一线治疗PD-L1阳性晚期非小细胞肺癌的III期OptiTROP-Lung05研究数据，结果显示联合组较帕博利珠单抗单药显著延长无进展生存期，总人群PFS风险比为0.35，12个月PFS率为62.4%对比29.0%；总生存期虽未成熟，但已观察到积极趋势。研报维持科伦博泰生物-B“买入”评级，未给出目标价。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983346","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641410503","title":"科倫博泰生物(06990)出現大手賣出1.98萬股，成交價$380.0，涉資752.4萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2641410503","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641410503?lang=zh_tw&edition=fundamental","pubTime":"2026-06-08 13:35","pubTimestamp":1780896900,"startTime":"0","endTime":"0","summary":"[大手成交]科伦博泰生物(06990)在下午01:35出现大手卖出，成交量为1.98万，成交价为港币$380.0，涉资752.4万。至目前为止，股价跌3.406%，今日最高价为$393.4，而最低价为$377.0，总成交量为40.85万股，总成交金额港币$1.56亿。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180815142908927_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180815142908927_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2606086446/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2606086446/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU0196878994.USD","BK1161","06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177037255","title":"異動解讀｜科倫博泰生物盤中下跌3.15%，董事長持續減持疊加業績虧損擴大延續拋壓","url":"https://stock-news.laohu8.com/highlight/detail?id=1177037255","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177037255?lang=zh_tw&edition=fundamental","pubTime":"2026-06-08 10:24","pubTimestamp":1780885440,"startTime":"0","endTime":"0","summary":"6月8日，科伦博泰生物盘中下跌3.15%，报381.8港元，成交额5525.37万港元。此外，公司此前披露的业绩显示，尽管营收增长6.5%至20.58亿元，但净亏损扩大至3.82亿元，授权及里程碑收入大幅减少、研发费用高企为主要拖累。尽管公司已发布回购授权计划并在ASCO大会获得重磅临床数据支撑，但董事长连续减持信号仍对短期市场信心构成压制。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641177986","title":"東方證券：國產創新藥開啓NSCLC一線治療範式革新","url":"https://stock-news.laohu8.com/highlight/detail?id=2641177986","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641177986?lang=zh_tw&edition=fundamental","pubTime":"2026-06-08 09:55","pubTimestamp":1780883706,"startTime":"0","endTime":"0","summary":"东方证券主要观点如下：一代PD-1单药±化疗标准松动，NSCLC一线进入二代IO、ADC+IO双线迭代周期本届ASCO大会上，来自国产创新药的三项重磅临床数据表明，NSCLC一线金标准，即传统的PD-1±化疗的正迎来系统性替代。在免疫1.0时代，国产创新药大多跟随海外PD-1药物的研发，如今快速发展至引领免疫2.0时代，有望创造肺癌千亿市场治疗范式的全面革新。该研究是全球首个ADC+IO一线NSCLC取得III期阳性结果，有望改写PD-L1阳性NSCLC一线用药格局。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451213.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2476274720.SGD","LU0348735423.USD","LU0455707207.USD","LU0561508036.HKD","LU1720050803.USD","BK0012","LU0417516571.SGD","LU0348766576.USD","LU2097828631.EUR","LU2476274308.USD","BK1574","LU2097828714.EUR","LU0348783233.USD","06990","IE00B543WZ88.USD","LU2488822045.USD","BK1161","LU0348825331.USD","LU2097828805.USD","LU0417516902.SGD","LU1961090484.USD","BK0183","LU0417516738.SGD","BK1564","09926","03958","LU0348784397.USD","IE00B5MMRT66.SGD","LU2328871848.SGD","LU2097828557.USD","BK1589","600958","LU0348827113.USD","LU0348767384.USD","159992","LU0634319403.HKD","01801","BK0028","LU0540923850.HKD","BK0276","IE00BPRC5H50.USD","LU1794554557.SGD","LU1969619763.USD","LU0502904849.HKD","HK0000165453.HKD","LU2097828474.EUR","BK1147","06978","LU0196878994.USD","LU2778985437.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152093512","title":"港股創新藥概念股普漲，康諾亞-B、科倫博泰生物升逾5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1152093512","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152093512?lang=zh_tw&edition=fundamental","pubTime":"2026-06-05 09:54","pubTimestamp":1780624485,"startTime":"0","endTime":"0","summary":"6月5日，港股创新药概念股普涨，$康诺亚-B(02162)$、$科伦博泰生物(06990)$涨超5%，$恒瑞医药(01276)$、$信达生物(01801)$涨超4%，$药明康德(02359)$、$歌礼制药-B(01672)$涨超3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/fd680cd945fd32917c8ece66ec685e5f","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fd680cd945fd32917c8ece66ec685e5f"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"df6be86a5967f2b571d48b8ac559bb5d","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162","BK4585","BK1161","BK1587","VXUS","06978","BK1583","BK1574","06990","BK4588","LU0196878994.USD","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641196028","title":"港股異動 | 科倫博泰生物(06990)升逾7% OptiTROP-Lung05研究實現里程碑突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2641196028","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641196028?lang=zh_tw&edition=fundamental","pubTime":"2026-06-05 09:45","pubTimestamp":1780623930,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科伦博泰生物涨超7%，截至发稿，涨6.87%，报417港元，成交额9442.01万港元。消息面上，据科伦博泰生物官微消息，在ASCO 2026年会上，公司芦康沙妥珠单抗联合帕博利珠单抗1L治疗晚期PD-L1阳性非小细胞肺癌的国内注册I川期临床OptiTROPLung05结果以口头汇报形式展示，该成果同时发表于《柳叶刀》。这是全球首个TROP2ADC联合免疫1L治疗NSCLC达到主要终点的I期研究。中金认为，该适应症在国内已经递交上市申请，未来有潜力重塑PD-L1阳性1L NSCLC治疗格局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450537.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK1161","BK4585","06990","BK4588","LU0196878994.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172136449","title":"異動解讀｜科倫博泰生物盤中上漲3.54%，回購計劃疊加ASCO臨床數據持續催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1172136449","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172136449?lang=zh_tw&edition=fundamental","pubTime":"2026-06-05 09:35","pubTimestamp":1780623318,"startTime":"0","endTime":"0","summary":"6月5日，科伦博泰生物盘中上涨3.54%，报405.8港元，成交额2817.64万港元。消息面上，公司于6月4日发布公告，拟提请股东大会审议授权董事会回购不超过已发行H股总数10%的股份，释放积极信号。此外，公司核心产品芦康沙妥珠单抗III期研究成果近期于ASCO大会口头报告并同步发表于《柳叶刀》，数据显示在PD-L1阳性非小细胞肺癌中PFS风险比达0.35，系全球首个在该适应症中显示PFS改善的ADC药物。此前该股因业绩亏损扩大及董事长减持一度承压，回购方案叠加重磅临床数据有助修复市场情绪。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152331396","title":"異動解讀｜科倫博泰生物開盤上漲3.08%，擬回購不超過10%已發行H股提振市場信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1152331396","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152331396?lang=zh_tw&edition=fundamental","pubTime":"2026-06-05 09:21","pubTimestamp":1780622505,"startTime":"0","endTime":"0","summary":"6月5日，科伦博泰生物开盘上涨3.08%，报402.2港元。消息面上，公司于6月4日发布公告，拟提请股东大会审议授权董事会回购不超过已发行H股总数10%的股份，回购计划释放积极信号。此外，公司核心产品芦康沙妥珠单抗III期研究成果近期于ASCO口头报告并同步发表于《柳叶刀》，双抗ADC SKB571新适应症II期临床也获NMPA批准，管线持续推进为股价提供支撑。此前该股因业绩亏损扩大及董事长减持一度承压，回购方案有助修复市场情绪。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}